Pharma, FDA Got A Bum Rap On Post-Market Studies, Booz Allen Report Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly 20 percent of post-marketing studies tagged in the agency's database as open had actually been fulfilled or released, according to the backlog review.